Statistical Tests And Outcomes
Help Questions
NAPLEX › Statistical Tests And Outcomes
A 28-year-old woman (weight 62 kg) with migraine is considering Preventive Drug H. In a trial, the mean reduction in monthly migraine days was 2.1 days with Drug H vs 1.4 days with placebo; mean difference $=0.7$ days with 95% CI $0.1$ to $1.3$, $p=0.02$. How does the confidence interval impact your decision on patient treatment?
Because $p=0.02$, the benefit is guaranteed to be at least 2 migraine days per month for most patients.
Because the CI includes positive values, the effect could be zero; therefore Drug H is not statistically significant.
Because the 95% CI does not include 0, the reduction is statistically significant; discuss whether a 0.7-day average benefit is clinically worthwhile for her.
Because the CI is above 1.0, the study shows Drug H increases migraine days and should be avoided.
Explanation
This question tests interpretation of mean differences and confidence intervals for continuous outcomes in migraine prevention. The critical statistical element is that the 95% confidence interval (0.1 to 1.3 days) excludes 0, confirming statistical significance of the 0.7-day reduction. The correct answer (A) properly recognizes statistical significance while appropriately questioning clinical significance of a modest benefit. Option B misunderstands confidence intervals for mean differences, which should exclude 0 (not include positive values) for significance. Option C incorrectly extrapolates from p-values to guarantee specific benefit magnitudes. Option D completely misinterprets the confidence interval, as values represent migraine day reductions, not increases. In pharmacy practice, distinguish between statistical significance (CI excludes null) and clinical significance (meaningful benefit to patient) - a 0.7-day average reduction may be worthwhile for some patients but not others, requiring shared decision-making about whether the benefit justifies treatment burden and cost.
A 66-year-old man (weight 78 kg) with COPD is considering Vaccine V to prevent hospitalization from respiratory infection. In a randomized trial, hospitalization occurred in 4.5% with Vaccine V vs 6.0% with placebo; RR $=0.75$ (95% CI $0.58$ to $0.97$), $p=0.03$. Which statistical finding is most crucial for assessing drug efficacy?
The placebo hospitalization rate only, because it proves the vaccine will work the same in all patients.
The $p$-value, because it indicates the size of the hospitalization reduction.
The RR of 0.75 with 95% CI excluding 1, supporting a statistically significant reduction in hospitalization risk.
The fact that the RR is not 0, meaning the vaccine has no effect.
Explanation
This question evaluates understanding of vaccine efficacy assessment using relative risk and confidence intervals. The key statistical finding is a relative risk of 0.75 with 95% confidence interval (0.58 to 0.97) excluding 1, demonstrating statistically significant reduction in hospitalization risk. The correct answer (A) appropriately identifies that the confidence interval excluding 1 confirms statistical significance of the 25% risk reduction. Option B incorrectly attributes effect size information to p-values, which only indicate significance probability. Option C illogically expects RR=0 for effectiveness, when any RR<1 indicates risk reduction. Option D inappropriately focuses on baseline risk alone without considering the treatment effect. For vaccine counseling in high-risk COPD patients, emphasize both the relative benefit (25% reduction) and absolute benefit (1.5% fewer hospitalizations), explaining that the confidence interval confirms this protection is real and not due to chance, supporting vaccination as an evidence-based preventive strategy.
A 50-year-old woman (weight 68 kg) with rheumatoid arthritis is choosing between Biologic J and Biologic K. In a comparative study, serious infection occurred in 3% with Biologic J vs 2% with Biologic K; OR $=1.52$ (95% CI $0.90$ to $2.56$), $p=0.12$, while clinical response rates were similar. What conclusion can be drawn from the odds ratio provided in the study for counseling about serious infection risk?
Because response rates were similar, the OR for infection should be ignored and risk is assumed identical.
The OR proves Biologic J is safer than Biologic K because it is greater than 1.
Because $p=0.12$, the infection risk difference is statistically significant and Biologic J should be avoided in all patients.
The OR shows a possible increased infection risk with Biologic J, but the 95% CI includes 1 and $p>0.05$, so a statistically significant difference is not established.
Explanation
This question addresses comparative safety assessment between biologics using odds ratios and confidence intervals. The critical statistical finding is that while OR=1.52 suggests potentially higher infection risk with Biologic J, the 95% confidence interval (0.90 to 2.56) includes 1 and p=0.12 > 0.05, indicating no statistically significant difference. The correct answer (A) properly interprets the non-significant finding while acknowledging the numerical trend. Option B incorrectly interprets OR>1 as indicating safety rather than increased risk. Option C inappropriately dismisses safety data based on similar efficacy, when both effectiveness and safety must be considered. Option D wrongly claims statistical significance when p>0.05 clearly indicates non-significance. In biologic selection for rheumatoid arthritis, non-significant safety differences with similar efficacy allow for individualized choice based on patient preferences, administration route, dosing frequency, and other patient-specific factors, while remaining vigilant for infection signs regardless of agent selected.
A 71-year-old man (74 kg) with heart failure with reduced ejection fraction is considering switching from enalapril to sacubitril/valsartan. In a trial, CV death occurred in 13.3% with sacubitril/valsartan vs 16.5% with enalapril (RR $=0.81$, 95% CI $0.73$ to $0.90$, $p<0.001$). Which statistical finding is most crucial for assessing drug efficacy in reducing CV death?
The RR $=0.81$ with a 95% CI $0.73$ to $0.90$, which excludes 1.0 and indicates a statistically significant reduction.
Only the p-value ($p<0.001$) is needed; effect size and CI do not matter for efficacy decisions.
Because the CI does not include 0, the RR is statistically significant.
Because the RR is not 0, the drug is effective.
Explanation
In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from clinical trials is essential for selecting optimal therapies to reduce cardiovascular mortality in heart failure patients. The key statistical factor influencing the decision is the 95% confidence interval excluding 1.0 around the relative risk, indicating statistical significance. The correct answer (A) best applies the statistical data by emphasizing the significant reduction in CV death with sacubitril/valsartan, guiding therapy switches. Choice B undervalues the role of effect size and CI in favor of p-value alone, while choice C simplistically assumes RR not equal to 0 implies efficacy without statistical context. Choice D misstates the null value for RR as 0 instead of 1.0 for significance testing. A transferable framework is to prioritize confidence intervals for assessing precision and significance of relative measures in trial data. This approach supports evidence-based decision-making by integrating statistics with patient outcomes for improved heart failure management.
A 62-year-old man (92 kg) with type 2 diabetes and established ASCVD is considering adding empagliflozin to metformin. In a randomized trial of empagliflozin vs placebo added to standard care, the primary composite CV outcome occurred in 10.5% vs 12.1% of patients, respectively (RR $=0.87$, 95% CI $0.78$ to $0.98$, $p=0.02$). He asks whether the study results support using empagliflozin to reduce CV events for someone like him. How does the confidence interval impact your decision on patient treatment?
The CI excludes 1.0, supporting a statistically significant reduction in CV events that can be considered in therapy selection.
The CI indicates only safety outcomes, so it cannot be used to guide a decision about efficacy.
The CI includes 1.0, so there is no evidence of benefit and empagliflozin should not be used for CV risk reduction.
Because the CI is narrow, the drug must provide a clinically large benefit regardless of absolute event rates.
Explanation
In pharmacy practice, applying statistical tests such as confidence intervals and p-values from clinical trials is essential for making evidence-based decisions on drug therapy for reducing cardiovascular risk in patients with type 2 diabetes and ASCVD. The key statistical factor influencing the decision is the 95% confidence interval around the relative risk, which excludes 1.0 and supports statistical significance. The correct answer (B) best applies the statistical data by recognizing that the CI excluding 1.0 indicates a significant reduction in CV events, supporting the use of empagliflozin in appropriate patients. Choice A misinterprets the CI as including 1.0 when it does not, leading to an incorrect conclusion of no benefit, while choice C wrongly assumes a narrow CI guarantees large clinical benefit without considering absolute rates. Choice D misapplies the CI by claiming it only addresses safety, ignoring its relevance to efficacy outcomes. A transferable skill for pharmacists is to always check if the confidence interval for relative risk excludes 1.0 to determine statistical significance, ensuring decisions balance efficacy, safety, and patient factors. This framework promotes evidence-based practice by integrating trial statistics with individualized care to optimize therapeutic outcomes.
A 68-year-old woman (60 kg) with nonvalvular atrial fibrillation is evaluating apixaban vs warfarin. In a clinical trial, major bleeding occurred in 2.1%/year with apixaban vs 3.1%/year with warfarin (RR $=0.68$, 95% CI $0.55$ to $0.83$, $p<0.001$), while stroke/systemic embolism was also reduced. Which statistical measure best supports the use of this medication for lowering bleeding risk?
A CI that excludes 0 confirms reduced bleeding risk because 0 is the null value for RR.
The p-value alone ($p<0.001$) proves the benefit is clinically large without considering effect size.
The RR $=0.68$ with a 95% CI that excludes 1.0, indicating a statistically significant reduction in major bleeding.
The absolute bleeding rates are irrelevant if the p-value is below 0.05.
Explanation
In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from clinical trials is vital for evaluating anticoagulant options to minimize bleeding risk in patients with atrial fibrillation. The key statistical factor influencing the decision is the relative risk of 0.68 with a 95% confidence interval excluding 1.0, confirming statistical significance. The correct answer (A) best applies the statistical data by highlighting the significant reduction in major bleeding with apixaban, supporting its preference over warfarin in suitable patients. Choice B overemphasizes the p-value alone without regard to effect size, while choice C incorrectly identifies 0 as the null value for relative risk instead of 1.0. Choice D dismisses absolute rates despite their importance in assessing clinical relevance alongside statistical significance. A transferable skill is to evaluate both relative measures and absolute event rates when interpreting trial outcomes for risk-benefit analysis. This framework fosters evidence-based pharmacy practice by integrating statistical evidence with patient-specific factors to enhance safety and efficacy.
A 39-year-old man (weight 88 kg) with major depressive disorder is considering switching to Antidepressant E. In a trial, remission occurred in 52% on Antidepressant E vs 46% on standard therapy; odds ratio (OR) $=1.27$ (95% CI $0.98$ to $1.65$), $p=0.07$. What conclusion can be drawn from the odds ratio provided in the study?
Because the 95% CI includes 1, the study does not show a statistically significant difference in remission; the apparent benefit is uncertain.
Because $p=0.07$ is less than 0.10, the result is always considered statistically significant in clinical trials.
Because OR is greater than 1, Antidepressant E is proven effective and should be recommended as first-line for all patients.
Because OR is used instead of RR, the direction of effect cannot be determined.
Explanation
This question tests understanding of odds ratios and confidence intervals in antidepressant efficacy assessment. The key statistical factor is that the 95% confidence interval (0.98 to 1.65) includes 1, indicating the study fails to demonstrate a statistically significant difference in remission rates. The correct answer (B) properly recognizes that when a confidence interval for an odds ratio includes 1, the apparent benefit is not statistically significant and remains uncertain. Option A incorrectly assumes OR>1 alone proves effectiveness without considering the confidence interval. Option C misapplies significance thresholds, as p=0.07 > 0.05 indicates non-significance regardless of being less than 0.10. Option D incorrectly suggests odds ratios cannot indicate direction of effect, when OR>1 clearly suggests higher odds of remission with the intervention. For clinical decision-making in psychiatry, remember that odds ratios approximate relative risks when outcomes are rare (<10%), but always evaluate the entire confidence interval to determine statistical significance before concluding treatment superiority.
A 48-year-old man (84 kg) with epilepsy is considering switching from immediate-release (IR) to extended-release (ER) levetiracetam. In a study, seizure-free status at 6 months was 72% with ER vs 70% with IR (RR $=1.03$, 95% CI $0.94$ to $1.13$, $p=0.51$), while adherence improved with ER. What is the clinical significance of the study's p-value in determining therapy?
The p-value indicates the study is invalid and results cannot be used.
A non-significant p-value proves ER and IR have identical adherence outcomes.
The p-value suggests no statistically significant difference in seizure freedom; ER may still be reasonable if adherence benefits outweigh cost/coverage issues.
Because $p=0.51$, ER is statistically superior for seizure control and should be mandated.
Explanation
In pharmacy practice, applying statistical tests such as p-values and relative risks from clinical studies is vital for formulation switches in epilepsy to improve adherence without compromising control. The key statistical factor influencing the decision is the p-value of 0.51, indicating no statistical significance in seizure freedom rates. The correct answer (A) best applies the statistical data by noting ER may be reasonable if adherence benefits justify, despite no superiority. Choice B misinterprets p-value as proving ER superiority, while choice C assumes non-significance means identical adherence. Choice D dismisses the study based on p-value. A transferable framework is to weigh non-significant efficacy against practical advantages like dosing convenience. This supports evidence-based decision-making by enhancing epilepsy management strategies.
A 29-year-old woman (62 kg) with migraine is considering a CGRP monoclonal antibody. In a trial, achieving
50% reduction in monthly migraine days occurred in 48% with drug vs 35% with placebo (OR $=1.71$, 95% CI $1.20$ to $2.44$, $p=0.003$). What conclusion can be drawn from the odds ratio provided in the study?
The OR indicates a 71% absolute increase in response rate.
Because the CI does not include 0, the OR is not significant.
The drug increases the odds of achieving the response compared with placebo, and the CI excluding 1.0 supports statistical significance.
Because OR is greater than 1, the drug decreases response.
Explanation
In pharmacy practice, applying statistical tests such as odds ratios and confidence intervals from clinical trials is crucial for evaluating migraine preventive therapies. The key statistical factor influencing the decision is the odds ratio of 1.71 with a 95% confidence interval excluding 1.0, supporting statistical significance. The correct answer (A) best applies the statistical data by concluding increased odds of response, aiding treatment choices. Choice B misinterprets OR as absolute increase, while choice C assumes OR >1 means decreased response. Choice D incorrectly claims CI must include 0 for non-significance. A transferable framework is to differentiate odds ratios from relative risks, especially for common outcomes. This promotes evidence-based decision-making by enhancing accuracy in interpreting efficacy data for neurology patients.
A 60-year-old man (76 kg) with BPH is considering tadalafil daily vs tamsulosin. A trial reported dizziness in 6% with tamsulosin vs 3% with tadalafil (RR $=2.0$, 95% CI $1.10$ to $3.64$, $p=0.02$). What statistical data supports the risk vs. benefit analysis when counseling about adverse effects?
Because $p=0.02$, tadalafil causes more dizziness than tamsulosin.
Because dizziness rates are under 10%, the RR cannot be interpreted and should not affect counseling.
RR $=2.0$ with a 95% CI above 1.0 indicates a statistically significant higher dizziness risk with tamsulosin.
A CI crossing 0 would be required to show increased risk for RR outcomes.
Explanation
In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from clinical trials is essential for adverse effect counseling in BPH treatments. The key statistical factor influencing the decision is the relative risk of 2.0 with a 95% confidence interval excluding 1.0, indicating statistical significance. The correct answer (A) best applies the statistical data by highlighting tamsulosin's higher dizziness risk, informing choices. Choice B dismisses RR based on low rates, while choice C misattributes higher risk to tadalafil. Choice D confuses requirement for CI crossing 0. A transferable framework is to use harm statistics for shared decision-making on tolerability. This enhances evidence-based practice by balancing efficacy and safety in urology counseling.